Blood Transfusion in Myocardial Infarction Opening Old Wounds for Comparative-Effectiveness Research∗ by Yeh, Robert W. & Wimmer, Neil J.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y VO L . 6 4 , N O . 8 , 2 0 1 4
ª 2 0 1 4 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 4 . 0 5 . 0 4 1EDITORIAL COMMENTBlood Transfusion in Myocardial Infarction
Opening Old Wounds for
Comparative-Effectiveness Research*Robert W. Yeh, MD, MSC,y Neil J. Wimmer, MD, MSCzSEE PAGE 811T he treatment of anemia in the general popu-lation of medical or surgical patients has longbeen an area of uncertainty, particularly with
regard to the transfusion of red blood cells. A multi-
tude of studies, conducted over >4 decades and
including 19 randomized controlled trials, have
sought to identify optimal transfusion strategies in
various patient populations. On the basis of these
studies, there has been an emerging consensus to
withhold red blood cell transfusion until a threshold
hemoglobin of 7 or 8 g/dl is reached in most clinical
scenarios (1,2). Red blood cell transfusions are associ-
ated with a number of adverse consequences, several
of which may be particularly concerning in patients
with cardiovascular disease (3). However, patients
who present with myocardial infarction (MI) may
also be particularly susceptible to the adverse conse-
quences of the reduced oxygen delivery imposed by
anemia. As such, patients with MI have been
excluded from nearly all previous randomized trials,
limiting our understanding of whether such patients
require a different threshold for transfusion than is
currently used for other conditions.
A cadre of observational studies has attempted to
ﬁll this void (4–7). These studies, involving diverse
patient populations, nonuniform data collection, and
a broad array of statistical methods, have produced
heterogeneous results. In the current issue of the*Editorials published in the Journal of the American College of Cardiology
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to disclose.Journal, Salisbury et al. (8) put forth a formidable
addition to this group, illuminating how the current
evidence basis on the role of transfusions in patients
with MI may be ﬂawed.Using a large electronicmedical record database, the
authors examined nearly 35,000 patients admitted
with MI at 57 centers between 2000 and 2008; a total
of 1,778 had received at least 1 blood transfusion. The
authors’ ﬁrst step was to identify a population of
transfused and nontransfused patients that could be
fairly compared with one another through the gen-
eration of propensity scores. This turned out to be no
easy task. Using a propensity model which incorpo-
rated critical factors that inﬂuence a clinician’s de-
cision to transfuse patients (most importantly, nadir
hemoglobin levels assessed during a hospitalization),
the authors found that >90% of the patients could
not be reasonably matched. The remaining w3,000
patients left for comparison bore little resemblance
to a typical population of MI patients, with only one-
quarter undergoing coronary angiography and <1 in
10 undergoing percutaneous coronary intervention.
These patients also had rates of chronic kidney dis-
ease that were 3 times that of the unmatched pop-
ulation and average nadir hemoglobin levels <9 g/dl.
Within this highly culled study population, blood
transfusions seemed to have a protective effect,
associated with a signiﬁcant 25% reduction in the
odds of in-hospital mortality. The signiﬁcance of this
last ﬁnding is rightly downplayed by the authors,
due to the questionable generalizability of the pop-
ulation that emerged after the matching process.
The results of this analysis and subsequent discus-
sion (8) offer a somewhat scathing rebuke of much of
the previous literature on the role of transfusions
among patients with coronary artery disease. Central
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821to this criticism is the notion that physicians are
highly selective about the patients they transfuse, and
that—more often than not—a transfused patient will be
sicker in various measureable and immeasurable ways
compared with another patient who the physician
thinks will do just as well without a blood transfusion.
Due to the inability of most databases to adequately
capture the factors governing physician decisions to
transfuse, as well as the inherent limitations in trying
to compare what may be fundamentally incomparable
patient populations, commonly used methods such as
multivariable regression or propensity score adjust-
ment may not adequately control for confounding
(9,10). Although this limitationmay cloud our ability to
meaningfully interpret much of the existing literature
on this topic, the broader implications for practicing
cardiologists are clear. After publication of >12 obser-
vational studies examining the association between
blood transfusion and outcomes in patients with sig-
niﬁcant cardiovascular disease, we are no closer now
to understanding the optimal way to treat anemia or
bleeding in these patients than we were a decade ago.
Without the guidance offered by strong evidence,
transfusion practices have varied signiﬁcantly across
providers and institutions. Among the participating
centers in the study by Salisbury et al. (8), there was a
2-fold variability in transfusion rates across hospitals
for 2 randomly selected patients with identical clin-
ical characteristics.
These are new injuries to old wounds in the area
of observational cardiovascular comparativeness-
effectiveness research. Whether it is a comparison of
treatments for carotid artery disease (11), different
coronary stent types in percutaneous coronary inter-
vention (12), or alternative revascularization strategies
for multivessel or left main coronary disease (13,14),
the nonrandomized nature by which clinicians make
treatment decisions—the thoughtful individualized
approach that one expects from a knowledgeable
physician—is precisely the factor which can doom
an observational comparison that is unable to codify
this thoughtfulness. Alternate methods including
those using instrumental variables (15) and falsiﬁca-
tion hypotheses (16) may be useful under these con-
ditions, but they have been slow to make their way
into the literature. Recognizing the limitations ofobservational analyses (including their own), the au-
thors (8) end their study with a call for “randomized
clinical trials . to determine appropriate blood
transfusion thresholds in patients with AMI.” Notably,
however, similar calls have been made in every one of
the previous observational studies examining this
topic over the past 20 years. Is this yet another voice
left to resonate in a chamber of echoes, unanswered?
Emerging studies suggest there may be reason
for optimism. Recently, 2 small, randomized pilot
studies were conducted comparing liberal and res-
trictive transfusion thresholds among patients with
signiﬁcant coronary artery disease (17,18). These
studies randomized 45 and 110 patients, respectively,
to treatment and had divergent results: the ﬁrst
showed a signiﬁcant increase in in-hospital death,
recurrent MI, or congestive heart failure with a more
liberal transfusion strategy, whereas the second
showed an increase in 30-day death with a more
restrictive strategy. Although these studies were too
small to provide any deﬁnitive answers for under-
standing the optimal transfusion threshold for MI
patients, they nevertheless represent important ﬁrst
attempts at offering much-needed randomized data
in this area. Recent innovations in clinical trial
execution involving more “pragmatic” designs (ie,
streamlined studies that can leverage existing regis-
try or electronic medical record infrastructure to
capture patient baseline data and outcomes) may be
ideal for a large yet relatively inexpensive random-
ized study of transfusion thresholds, a necessary
quality for a study that is unlikely to ﬁnd an industry
sponsor (19–21). Armed with new, more efﬁcient
mechanisms for randomized comparisons that can
better leverage the growing body of data routinely
collected in the course of clinical care, perhaps we
have reached an inﬂection point that can allow such a
trial to take place. Until then, the wide variation in
transfusion practices across hospitals is likely to
persist, as clinicians sift through the varied offerings
of a growing number of observational comparisons.
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